Regulatory Processes for Rare Disease Drugs in the United States and European Union
Book Details
AI Summary
Delivery Location
Delivery fee: Select location
Rare diseases, such as sickle cell disease and thalassemia, affect up to 30 million people in the United States and at least 300 million across the globe. Congress called on the U.S. Food and Drug Administration (FDA) to sponsor a National Academies study on processes for evaluating the safety and efficacy of drugs for rare diseases or conditions in the United States and the European Union. The resulting report provides recommendations for enhancing and promoting rare disease drug development by improving engagement with people affected by a rare disease, advancing regulatory science, and fostering collaboration between FDA and the European Medicines Agency.
Get Regulatory Processes for Rare Disease Drugs in the United States and European Union by at the best price and quality guaranteed only at Werezi Africa's largest book ecommerce store. The book was published by National Academies Press and it has pages.
Discover books you might love based on this title.
More in This Genre
Dietary Reference Intakes for Energy
Ksh 9,550.00
Neuroscience Biomarkers and Biosignatures
Ksh 9,350.00
First FRCR Anatomy
Ksh 8,100.00
Exercise Programming for Older Adults
Ksh 34,200.00
The Private Sector as a Catalyst for Health Equity and a Vibrant Economy
Ksh 5,950.00
ALL ABOUT GOUT
Ksh 1,250.00
